April 2011
Volume 52, Issue 14
ARVO Annual Meeting Abstract  |   April 2011
A20 Zinc Finger Protein in the Regulation of TNF-α Signaling in Human Glaucoma
Author Affiliations & Notes
  • Xiangjun Yang
    Ophthalmology & Visual Sciences,
    University of Louisville, Louisville, Kentucky
  • Cheng Luo
    Ophthalmology & Visual Sciences,
    University of Louisville, Louisville, Kentucky
  • Jian Cai
    Pharmacology & Toxicology,
    University of Louisville, Louisville, Kentucky
  • David W. Powell
    Biochemistry & Molecular Biology,
    University of Louisville, Louisville, Kentucky
  • Markus H. Kuehn
    Ophthalmology & Visual Sciences, University of Iowa, Iowa City, Iowa
  • Gulgun Tezel
    Ophthalmology & Visual Sciences,
    Anatomical Sciences & Neurobiology,
    University of Louisville, Louisville, Kentucky
  • Footnotes
    Commercial Relationships  Xiangjun Yang, None; Cheng Luo, None; Jian Cai, None; David W. Powell, None; Markus H. Kuehn, None; Gulgun Tezel, None
  • Footnotes
    Support  NEI grants (R01 EY013813, R01 EY017131, R24 EY015636), and RPB
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 3107. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Xiangjun Yang, Cheng Luo, Jian Cai, David W. Powell, Markus H. Kuehn, Gulgun Tezel; A20 Zinc Finger Protein in the Regulation of TNF-α Signaling in Human Glaucoma. Invest. Ophthalmol. Vis. Sci. 2011;52(14):3107.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : Growing evidence supports the involvement of TNF-α signaling in glaucomatous neurodegeneration. Since TNF-α signaling may lead to cell death- or cell survival-promoting diverse bioactivities, ongoing studies using proteomic analysis techniques aim to identify specific target molecules for treatment of glaucoma.

Methods: : Human retinal protein samples were obtained from age-matched twenty donors with (n:10) or without (n:10) glaucoma and were individually analyzed by quantitative 2D-LC-MS/MS. Western blot analysis was utilized for further validation of the MS/MS data, and the cellular localization of selected proteins was determined by immunohistochemical analysis of an additional group of glaucomatous human donor eyes (n:38) and controls (n:30).

Results: : Differentially regulated retinal proteins in human glaucoma included a number of downstream adaptor/interacting proteins and kinases involved in the TNF-α signaling. Bioinformatic analysis of the high-throughput proteomic data established extended functional networks with links to the TNF-α-mediated death- or survival-promoting pathways. An interesting observation was that one of the regulatory molecules, ubiquitin-editing zinc finger protein A20 (also known as Tumor Necrosis Factor Alpha-Induced Protein 3, TNFAIP3), exhibited prominent differences between individual glaucomatous samples. Following set of experiments were focused on this potent inhibitor of NF-ΚB activation and negative regulator of the TNF-α signaling leading to apoptosis, stress response, and inflammation. Quantitative Western blot analysis using a specific antibody validated individual variabilities in A20 expression (over two-fold up-regulation in 4 out of 10 glaucomatous samples versus unchanged or down-regulated expression in rest of the samples). Tissue immunolabeling demonstrated A20 localization in astrocytes and RGCs. Furthermore, the Ingenuity Pathways Analysis pointed out the mechanisms of action that A20 regulates TNF-α-mediated cell death and immunity through diverse interactions with various signaling components (besides NF-ΚB, including those recently associated with glaucomatous neurodegeneration, such as 14-3-3 proteins and toll-like receptors).

Conclusions: : These findings highlight many important molecules involved in the TNF-α signaling in human glaucoma. Better understanding of the regulatory pathways of TNF-α signaling, as well as the molecular basis of individual differences, can further benefit the development of new treatment strategies for glaucoma.

Keywords: proteomics • ganglion cells • neuroprotection 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.